Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 known ✓ | O43526 | 2/20 | 0.51 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 2/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16820451 | 1.00 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL6911757 | 0.98 | LMNA (0.56) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL67237 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL20769804 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL1715 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL65737 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL29757088 | 0.98 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL9171150 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL5598361 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Methane SCHEMBL7338694 | 0.96 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219156-A1 | METHOD FOR PRODUCING AMINO ACID AND PEPTIDE COMPOUND, USING ENZYME AND ADDITIVE | 中外製薬株式会社 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023127752-A1 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | 中外製薬株式会社 | 2023-07-06 | — | — | WO | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-107188808-A | A kind of synthetic method of the phenylbutyric acid hydrochloride of 4 amino 3 | 江苏斯威森生物医药工程研究中心有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-206417438-U | A kind of hydrochloric acid tank for being used to prepare the phenylbutyric acid hydrochloride of 4 amino 3 | 浙江邦成化工有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-206417438-U | A kind of hydrochloric acid tank for being used to prepare the phenylbutyric acid hydrochloride of 4 amino 3 | 浙江邦成化工有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9617212-B2 | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors | CONTROLLED CHEMICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2015095052-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-6043397-A | REACTING AN AROMATIC COMPOUND HAVING CARBONYL HALIDE, ALDEHYDE OR KETONE GROUPS, AND OPTIONALLY HALOGEN GROUPS WITH A DI(ALKYL/PHENYL)AMINOSULFUR TRIFLUORIDE; REACTION CAN PROCEED IN STANDARD VESSEL AT AMBIENT TEMPERATURE, PRESSURE | NIPPON SHOKUBAI CO., LTD. (JP) | 2000-03-28 | — | — | US | disclosed |
| CN-1041309-C | Piperiding derivatives | LILLY CO ELI (US) | 1998-12-23 | — | — | CN | disclosed |
| CN-1065455-A | Piperidine derivative | LILLY CO ELI (US) | 1992-10-21 | — | — | CN | disclosed |
| US-4478837-A | HYPOTENSIVE AGENTS | SANDOZ LTD. (CH) | 1984-10-23 | — | — | US | disclosed |
| US-4395410-A | Quaternary ammonium antiarrhythmic drugs | ELI LILLY AND COMPANY (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0002604-B1 | QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4289787-A | PROLONG ACTION POTENTIAL OF CARDIAC TISSUE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
| US-4140770-A | Benzoylethers and processes for their production | A. NATTERMANN & CIE. GMBH (DE) | 1979-02-20 | — | — | US | disclosed |
| US-3954754-A | ANTIHYPERTENSIVES | SANDOZ LTD. (CH) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | MIF, MACF1, MYADM | KCNQ2 4316/4885GAA 3343/4885HTR1A 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.